What is Veradermics 's short-term investments?

Veradermics (MANE) reported short-term investments of $222.39M in Q1 2026.

What does short-term investments mean?

Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Veradermics MANE Short-Term Investments

Short-Term Investments at other companies

UnifirstUNF

$5.66M-35.7%

Alignment HealthcareALHC

$20.71M-37.9%

Dianthus TherapeuticsDNTH

$483.59M+91.1%

10x Genomics, Inc.TXG

$49.56M-0.6%

IPG PhotonicsIPGP

$332.14M-41.1%

QuantumScape Corporation QS

$759.64M+7.5%

Other financials

Income statement

See full

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

See full

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

See full

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

See full

Market cap$4.99B+296%

Returns & leverage

See full

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veradermics 's short-term investments?: Veradermics (MANE) reported short-term investments of $222.39M in Q1 2026.
What does short-term investments mean?: Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.